Chen Ji, Feng Xiaoli, Dong Mei
Department of Medical Oncology, The Seventh People's Hospital of Chengdu, Chengdu Cancer Hospital, Chengdu 610041, China.
Department of Pathology, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College Beijing 100021, China.
Int J Clin Exp Pathol. 2015 Feb 1;8(2):2123-30. eCollection 2015.
Anaplastic lymphoma kinase (ALK)-positive diffuse large B-cell lymphoma (DLBCL) is a rare subtype of non-Hodgkin's lymphoma (NHL) with distinct morphologic and immunohistochemical features. We reported a 57-year-old female with ALK-positive DLBCL in her left nasal cavity. Histologically, the tumor cells were characterized by plasmablastic morphology and tested positive for ALK in a cytoplasmic granular staining pattern. The neoplastic cells were positive for CD38, CD4, MUM1, CD138 and Vimentin. However, they failed to express CD56, CD30, as well as mature B cells markers, such as CD79a, CD20 and T cells markers such as CD2, CD3, CD5, CD7 and CD8. The patient achieved complete response after four cycles of CHOEP (cyclophosphamide, doxorubicin, vincristine, prednisone, and etoposide) treatment. Then she received radiotherapy of the originally involved area. This case represented a rare ALK-positive DLBCL in the nasal region.
间变性淋巴瘤激酶（ALK）阳性弥漫性大B细胞淋巴瘤（DLBCL）是一种罕见的非霍奇金淋巴瘤（NHL）亚型，具有独特的形态学和免疫组化特征。我们报告了一名57岁女性，其左鼻腔患有ALK阳性DLBCL。组织学上，肿瘤细胞具有浆母细胞形态，ALK检测呈阳性，表现为细胞质颗粒状染色模式。肿瘤细胞CD38、CD4、MUM1、CD138和波形蛋白呈阳性。然而，它们不表达CD56、CD30以及成熟B细胞标志物如CD79a、CD20，也不表达T细胞标志物如CD2、CD3、CD5、CD7和CD8。该患者在接受四个周期的CHOEP（环磷酰胺、阿霉素、长春新碱、泼尼松和依托泊苷）治疗后达到完全缓解。然后她接受了原发病灶区域的放疗。该病例代表了鼻腔区域罕见的ALK阳性DLBCL。
